Parasitic infections related to anti-type 2 immunity monoclonal antibodies: a disproportionality analysis in the food and drug administration’s adverse event reporting system (FAERS)

Introduction: Monoclonal antibodies (mAbs) targeting immunoglobulin E (IgE) [omalizumab], type 2 (T2) cytokine interleukin (IL) 5 [mepolizumab, reslizumab], IL-4 Receptor (R) α [dupilumab], and IL-5R [benralizumab]), improve quality of life in patients with T2-driven inflammatory diseases. However,...

Celý popis

Podrobná bibliografia

Vydané v:	Frontiers in pharmacology Ročník 14; s. 1276340
Hlavní autori:	Pera, Victor, Brusselle, Guy G., Riemann, Sebastian, Kors, Jan A., Van Mulligen, Erik M., Parry, Rowan, de Wilde, Marcel, Rijnbeek, Peter R., Verhamme, Katia M. C.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Frontiers Media S.A 14.11.2023
Predmet:	biologicals disproportionality analysis FAERS monoclonal antibodies parasitic infections Pharmacology spontaneous reporting
ISSN:	1663-9812, 1663-9812
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!